Heartseed entered into an exclusive technology partnership and licensing agreement with Novo Nordisk for allogeneic iPS cell-derived cardiac muscle spheres for severe heart failure. The circumstances surrounding the agreement emerged through interviews with people involved with Heartseed.
On 1 June 2021, Heartseed announced that it had entered into an exclusive technology partnership and licensing agreement with Novo Nordisk for HS-001, an allogeneic iPS cell-derived cardiac muscle sphere for severe heart failure.
The total value of the agreement was reportedly up to ¥65.5 billion. The background and circumstances surrounding the agreement were detailed in an interview on 23 June of the same year with Heartseed Director and COO Yasui Kikuhisa (安井季久央).
Heartseed is advancing the development of regenerative medicine in the heart-failure field. An interview at the time noted that the due-diligence process for this partnership had been an all-out effort.